Physician profile
Jill E Breeze
NPI 1700812914
$1,065.72
in general payments reported to CMS, 2019-2025
14 companies · $403 in 2025
The $403 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.44 · 2020: $103 · 2021: $153 · 2022: $95.18 · 2023: $136 · 2024: $122 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $355 · Honoraria: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.29 |
| Honoraria | $306.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $306.50 | 2025 | Spinosad, Natroba |
| Pfizer INC. | $125.91 | 2021-2025 | |
| Glaxosmithkline, LLC. | $110.11 | 2020-2024 | Bexsero |
| Supernus Pharmaceuticals, INC. | $108.69 | 2021-2024 | Qelbree, Qelbree |
| Sanofi Pasteur INC. | $80.11 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.96 | 2020-2021 | |
| Corium, LLC | $70.86 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $58.91 | 2019-2023 | Jornay Pm |
| Adlon Therapeutics L.P. | $38.50 | 2020-2021 | |
| Genentech USA, INC. | $32.56 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $17.24 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $16.19 | 2025 | Gardasil 9, Rotateq, Enflonsia |
| Kowa Pharmaceuticals America, INC. | $15.55 | 2025 | Zoryve |
| Tris Pharma INC | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Breeze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.